Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property

DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India

By The Northwire Desk — AI Analysis Jan 22, 2026 · 17:01 DTR · 0.55 DiagnosTear Technologies Inc.
DTR · Price

Executive Summary

  • DiagnosTear Technologies Inc. signed a non‑binding Letter of Intent with Renovate Biologicals Pvt. Ltd. to evaluate and potentially distribute its CE‑IVD approved dry‑eye diagnostic test, TeaRx™, in India through April 30 2026.
  • The LOI grants Renovate exclusive market‑facing rights for the evaluation period and sets a target to negotiate a definitive commercial agreement by June 1 2026.
  • This partnership expands DiagnosTear’s commercialization footprint into one of the world’s largest ophthalmic markets, supporting its global rollout strategy for TeaRx™.

Key Details

  • Parties: DiagnosTear Technologies Inc. (CSE: DTR) and Renovate Biologicals Pvt. Ltd., a Hyderabad‑based ophthalmic distribution company.
  • Product Covered: TeaRx™ – a CE‑IVD approved rapid point‑of‑care test for dry eye disease using tear‑fluid analysis.
  • LOI Scope:
  • Renovate will exclusively lead market‑facing activities (engagement with ophthalmologists, clinics, KOLs) in India during the LOI Period (until 30 April 2026).
  • Activities include assessing commercial demand, adoption potential, pricing structure, distribution strategy, and long‑term collaboration models.
  • Milestones: Parties aim to reach a definitive commercial agreement by 1 June 2026 following the evaluation period.
  • Strategic Rationale: India represents a large, fast‑growing ophthalmic market; the partnership is intended to accelerate TeaRx™’s entry and scale in the region.
  • Management Quote: “India is a strategically important market for DiagnosTear… This LOI reflects our continued effort toward building a strong international distribution network and accelerating the commercial rollout of TeaRx™ globally,” said Dr. Shimon Gross, CEO.

Notable Quotes

“India is a strategically important market for DiagnosTear, with a large patient population and growing demand for efficient, point‑of‑care diagnostic solutions,” – Dr. Shimon Gross, CEO, DiagnosTear Technologies Inc.

Read the original news release →

More from DiagnosTear Technologies Inc.

Jun 05, 2026 · 08:31

DiagnosTear’s TeaRx Validation Fails to Halt 65% Decline as CLARIFY Royalties Weigh on Near-Term Upside

Other May 12, 2026 · 16:06

DiagnosTear Solidifies CLARIFY License, Moving from Dry-Eye to Blood Diagnostics, but Commercialization Cliff Looms

Other Feb 26, 2026 · 17:01

DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye

Regulatory Feb 20, 2026 · 17:01

DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

M&A / Property Dec 17, 2025 · 18:01

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Other Dec 02, 2025 · 17:01

DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test

Other